TOP TIERMARKET NEWSWIRE

News & sentiment

ARROWHEAD PHARMACEUT (ARWR) — News & AI sentiment

ARROWHEAD PHARMACEUT (ARWR) news roundup. 17 stories aggregated over the last 30 days. Average 30-day sentiment is 64.5/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 2 sales totalling $1.2M — net selling of $1.2M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

17

avg sentiment 64.5/100

Insider net (90d)

$1.2M

0 buys · 2 sells

Congress (90d)

0

0 buys · 0 sells

ARWR news in the last 24 hours, 7 days, 30 days and 90 days

How much ARWR coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ARWR stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	17	64.5/100	ARWR headlines →
Last 90 days	59	59.8/100	ARWR headlines →

Latest stories on ARWR

Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia

Seeking Alpha64 · neutralanalyst

Oct 21

Cantor Fitzgerald reiterates Arrowhead Pharma stock rating on trial data

Investing.com Analyst Ratings53 · neutralanalyst

Oct 15

Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

Seeking Alpha74 · bullishproduct/pr

Oct 15

H.C. Wainwright reiterates Arrowhead Pharma stock rating on tau data

Investing.com Analyst Ratings52 · neutralanalyst

Oct 15

Arrowhead assumed with a Buy at UBS

The Fly63 · neutralanalyst

Oct 15

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow

Seeking Alpha56 · neutralproduct/pr

Oct 14

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Stocktwits News74 · bullishproduct/pr

Oct 14

Arrowhead spikes after early-stage trial data for Alzheimer’s disease

Seeking Alpha74 · bullishproduct/pr

Oct 14

ARWR Highlights ARO-MAPT’s 73% Mean Tau Reduction at Day 105, Pointing to Potential Quarterly Dosing October 14, 2026

MarketChameleon67 · bullishproduct/pr

Oct 14

Why is Arrowhead Pharmaceuticals stock surging today?

Investing.com Markets72 · bullishgeneral

Oct 14

Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT

The Fly56 · neutralproduct/pr

Oct 14

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

StockTitan64 · neutralproduct/pr

Oct 14

Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM

GlobeNewswire63 · neutralproduct/pr

Oct 7

Arrowhead announces US FDA granted plozasiran entry into STAR program

The Fly67 · bullishproduct/pr

Oct 7

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

StockTitan67 · bullishproduct/pr

Oct 7

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Seeking Alpha67 · bullishproduct/pr

Oct 3

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

StockTitan63 · neutralproduct/pr

Sep 29

Alpha-1 Antitrypsin Deficiency Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma

Barchart64 · neutralgeneral

Sep 28

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

Stocktwits News63 · neutralanalyst

Sep 24

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating

Investing.com Analyst Ratings50 · neutralanalyst

Sep 24

Arrowhead resumed with a Neutral at Goldman Sachs

The Fly50 · neutralanalyst

Sep 24

One year in, Arrowhead Intermediaries advances integration with brand alignment

Business Insider56 · neutralgeneral

Sep 22

RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics

GlobeNewswire50 · neutralgeneral

Sep 18

Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’

Stocktwits News58 · neutralproduct/pr

Sep 16

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Seeking Alpha55 · neutralgeneral

Sep 16

Open ARWR in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →